https://www.selleckchem.com/pr....oducts/gsk2126458.ht
There was no evidence of an increased rate of bacterial resistance but was associated to respiratory adverse effects. Evidence is not robust enough to confirm a benefit of inhaled Tobramycin in reducing P. aeruginosa sputum density or eradication. There was a high attrition rate, in part due to respiratory adverse events after drug administration, which affects interpretation of the data and raises concerns about the tolerability of the drug. Further network meta-analysis should be done to compare the efficacy and safety of different